Posts by: Iqra Mumal

News

High levels of C-reactive protein, a marker of systemic inflammation, at the onset of back pain can help predict which patients go on to develop ankylosing spondylitis, a study ... Read more

November 26, 2018November 26, 2018

Genetic Marker HLA-B27 Correlates With Ankylosing Spondylitis Onset but Not Disease Burden, Study Shows

News

The presence of a specific genetic marker called HLA-B27 in Caucasian ankylosing spondylitis patients is related to earlier disease onset and higher disease prevalence among family members, a study has found. However, ... Read more

October 29, 2018October 29, 2018

Anti-Rheumatic or Anti-Tumor Necrosis Therapy Does Not Contribute to Increased Infection Risk, Study Shows

News

Patients with ankylosing spondylitis treated with anti-rheumatic drugs or anti-tumor necrosis therapy are not more likely to develop infections compared to non-users, a study shows. The study, “Use of ... Read more

September 7, 2018September 7, 2018

Ankylosing Spondylitis Patients Have Different Biodiversity in Gut, Study Finds

News

Patients with ankylosing spondylitis have differences in the diversity of the fungi and bacterial populations that reside in the gut compared with healthy individuals, a study shows. The study, ... Read more

September 5, 2018September 5, 2018

Biologics, Anti-TNF Therapy Protect AS Patients Against Heart Disease, Study Suggests

News

Anti-TNF therapy and other biologics — often used for the treatment of inflammatory arthritis — partially protect ankylosing spondylitis patients from heart disease, according to Australian researchers. Their study, ... Read more

August 1, 2018August 1, 2018

Blocking IL-23 Not Sufficient to Treat Ankylosing Spondylitis, Phase 2 Trial Finds

News

Inhibiting IL-23, a molecule involved in inflammation, was not found to be clinically meaningful to treat ankylosing spondylitis, according to the results from a Phase 2 trial. The study, ... Read more

July 2, 2018July 2, 2018

Eli Lilly Announces Positive Results from Its 2nd Phase 3 Trial of Ixekizumab

News

Treatment with Eli Lilly’s monoclonal antibody Taltz (ixekizumab) significantly improved the signs and symptoms of ankylosing spondylitis in patients participating in a Phase 3 clinical trial, results show. The study, called COAST-W (NCT02696798), met ... Read more

May 15, 2018May 15, 2018

Patient Support Services Linked with Better Health Outcomes in Ankylosing Spondylitis Patients

News

Ankylosing spondylitis patients who receive tailored, personalized services, such as care coach calls, have a higher probability of achieving controlled disease within six to 18 months, a study shows. The ... Read more

May 7, 2018May 7, 2018

Ankylosing Spondylitis Patients More Likely to Develop COPD, Researchers Find

News

Patients with ankylosing spondylitis are more likely to develop a lung disorder known as chronic obstructive pulmonary disease (COPD) compared to the rest of the population, according to researchers. ... Read more

Posts by: Iqra Mumal

Iqra Mumal

High Levels of C-reactive Protein Can Predict Risk for Future Ankylosing Spondylitis, Study Finds

Genetic Marker HLA-B27 Correlates With Ankylosing Spondylitis Onset but Not Disease Burden, Study Shows

Anti-Rheumatic or Anti-Tumor Necrosis Therapy Does Not Contribute to Increased Infection Risk, Study Shows

Ankylosing Spondylitis Patients Have Different Biodiversity in Gut, Study Finds

Biologics, Anti-TNF Therapy Protect AS Patients Against Heart Disease, Study Suggests

Blocking IL-23 Not Sufficient to Treat Ankylosing Spondylitis, Phase 2 Trial Finds

Eli Lilly Announces Positive Results from Its 2nd Phase 3 Trial of Ixekizumab

Patient Support Services Linked with Better Health Outcomes in Ankylosing Spondylitis Patients

Ankylosing Spondylitis Patients More Likely to Develop COPD, Researchers Find

Pin It on Pinterest